CiPA-Ready hiPSC Cardiomyocytes for Cardiac Safety Assessment

Drug-induced arrhythmias remain a significant challenge in pharmaceutical development, often resulting in late-stage failure, regulatory rejection and post-market withdrawals. Traditional safety assays focused on hERG potassium channel inhibition and QT prolongation, while effective at detecting torsadogenic compounds, frequently overestimate risk for multichannel-acting drugs and underestimate chronic structural toxicity.[1,2] Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have emerged as a superior human-relevant alternative, particularly when integrated into the Comprehensive *in vitro* Proarrhythmia Assay (CiPA) framework.[2,3] CiPA-ready hiPSC-CM platforms offer a convergent solution that combines physiological relevance, mechanistic insight and regulatory alignment, positioning them as pivotal tools for next-generation cardiac safety assessment.[1,2,3]

The Need for Better Cardiac Safety Testing

Cardiovascular toxicity remains a leading cause of late-stage drug development failure and post-marketing withdrawal. Historical analyses show that 8.7% of drugs withdrawn between 1960 and 1999, and 14% withdrawn between 1953 and 2013, were due to unanticipated cardiotoxic effects.[4,5] These failures span diverse therapeutic classes, antiarrhythmics like dronedarone, anticancer agents including anthracyclines, and non-cardiac drugs such as antidiabetics, fluoroquinolones and SSRIs.[1,6,7,8]

Current regulatory paradigms mandate hERG channel testing and QT interval assessment.[1] While valuable, these approaches have inherent limitations. Single-channel focus can overestimate clinical risk for drugs with beneficial multichannel effects (e.g., verapamil blocking both hERG and L-type calcium channels, or ranolazine modulating late sodium current), leading to unnecessary rejection of potentially useful compounds.[1,9] Additionally, conventional assays fail to capture chronic functional decline, structural injury, metabolic dysfunction and complex arrhythmic mechanisms.[1]

The CiPA initiative integrates three complementary methodologies: 1. quantitative *in vitro* ion channel electrophysiology, 2. *in silico* human ventricular action potential modelling and 3. human hiPSC-CM functional assays capturing integrated cellular responses.[2,3] This multitiered approach enables evaluation of repolarisation, QT prolongation, beat rate, conduction, contractility and emergent arrhythmic phenotypes within a human-relevant context.[1]

Generating and Characterising CiPA-Ready hiPSC-Derived Cardiomyocytes

Successful CiPA implementation requires consistent production of large cell batches with reproducible structural, molecular and electrophysiological properties. hiPSC lines are expanded feeder-free on hESC-qualified matrix in defined medium, passaged at ~80% confluency to preserve genomic stability and differentiation competence.[1] Cardiomyocyte



Figure 1. Directed differentiation and characterisation of hiPSC-derived cardiomyocytes. (A) Schematic of the stepwise differentiation from hiPSC expansion through mesoderm and cardiac progenitor stages to cardiomyocytes. (B) Representative phase-contrast images at defined time points illustrating morphological changes during differentiation. (C) Flow cytometric analysis confirming expression of cardiac markers cardiac troponin, α-actinin, MLC2v and MLC2a in the differentiated population. (D) Immunofluorescence staining of differentiated cardiomyocytes for cardiac troponin, α-actinin, MLC2v and MLC2a (scale bar: 10 μm).

differentiation employs monolayer-based protocols with stage-specific Wnt modulation and progressing through mesodermal induction and cardiac progenitor specification to autonomously contracting ventricular-like cardiomyocytes by days.[10–15] Phenotypic characterisation is essential for platform qualification. Immunofluorescence microscopy and flow cytometry of day 20 YBLiCardio cells demonstrate high expression of canonical sarcomeric markers, cardiac troponin T (cTnT, ~91%), alpha-actinin (~93%) and ventricular myosin light chain isoforms MLC2v and MLC2a (~80–81%), supporting their classification as mature, ventricular-enriched cardiomyocytes suitable for electrophysiological safety assessment (Figure. 1).[1,11]

Quantitative RT-PCR reveals a sharp temporal transition during differentiation. Cardiac-specific genes (TNNT2, MYL2, MYH7) remain undetectable in undifferentiated hiPSCs but increase dramatically after day 15, while pluripotency-associated transcripts (hTERT) progressively decline, confirming authentic ventricular cardiomyocyte identity.[1]

Transcriptomic Maturation and Alignment with Adult Heart

A persistent criticism of hiPSC-CMs is their "fetal-like" phenotype, potentially limiting translational relevance for adult cardiac safety. Comparative RNA sequencing of hiPSC-CMs at sequential stages (days 6, 15, 30) versus adult human heart RNA reveals time-dependent maturation.[1] Principal component analysis shows undifferentiated hiPSCs segregating distinctly from cardiomyocytes and heart tissue, while later-stage hiPSC-CMs progressively cluster toward adult heart reference, indicating convergent transcriptional programmes.[1] Focused gene set analysis demonstrates substantial alignment with native heart tissue. Pluripotency markers (NANOG, SOX2) decline progressively, cardiac transcription factors (GATA4, TBX5, NKX2-5, MEF2C) approach adult levels, sarcomeric genes (ACTC1, ACTN2) show robust expression and ion channel genes critical for depolarisation/repolarisation (SCN5A, KCNQ1, KCNH2) exhibit expression levels comparable to native myocardium.[1] Day 30 hiPSC-CMs show enhanced expression of functional genes (MYL2, CASQ2, CAMK2D) relative to day 15, confirming progressive maturation toward an adult-like phenotype.[1]

Functional Pharmacology: Acute and Chronic Responses

Functional validation using CardioExcyte or FLEXcyte MEA platforms enables simultaneous recording of extracellular field potentials across 96 wells, systematically evaluating acute and chronic drug responses.[1]

Acute studies with canonical ion channel modulators demonstrate expected pharmacological signatures. Nifedipine (L-type Ca^{2+} blocker) produces concentration-dependent amplitude reduction and contraction shortening, consistent with suppressed calcium-dependent excitation–contraction coupling.[1] Lidocaine (Na^{+} blocker) induces negative inotropy and upstroke/recovery prolongation.[1] E-4031 (hERG blocker) produces marked beat duration prolongation, negative inotropy and spontaneous arrhythmias, mirroring its known proarrhythmic liability.[1] Isoproterenol (β-agonist) increases amplitude and beat rate at submicromolar concentrations, and desensitisation at high doses illustrates biphasic adrenergic modulation.[1] Carbachol (muscarinic agonist) prolongs action potential duration and decreases beat rate, indicating functional parasympathetic modulation and mixed atrial–ventricular phenotype.[1]



Chronic monitoring over 72 hours reveals time- and concentration-dependent functional deterioration. Doxorubicin (anthracycline) induces progressive amplitude reduction with eventual beat cessation at higher concentrations.[1] Sunitinib (multi-targeted tyrosine kinase inhibitor) produces concentration-dependent reductions in amplitude and beat rate with rapid functional collapse.[1] In contrast, erlotinib (a lower-risk tyrosine kinase inhibitor) shows minimal effects, supporting low-risk classification.[1] Pentamidine (hERG trafficking blocker) produces a gradual amplitude decline with eventual beat cessation, plus duration prolongation and altered contractile slopes.[1]

These datasets illustrate how well-characterised hiPSC-CM systems connect molecular targets to integrated electrophysiological and contractile phenotypes over clinically relevant timescales.[1]

CiPA Risk Stratification and Compound Classification

CiPA-ready platforms detect and classify drug-induced QT prolongation and proarrhythmic risk concordant with human clinical outcomes[1,2,3] by measuring field potential duration (FPD) normalised to vehicle control.1 In this study, FPD prolongation bands of ≤113% (low), 113–139% (intermediate) and ≥165% (high) were used for TdP risk categorisation, aligned with ranges reported in HESI/CiPA validation studies.[1,14]

Applied to the HESI CiPA reference panel, robust hiPSC-CM platforms show: 1. minimal FPD changes for low-risk agents (mexiletine, ranolazine), 2. graded prolongation for intermediate-risk compounds (antipsychotics, antihistamines) and 3. marked prolongation and electrophysiological instability for high-risk compounds (dofetilide, sotalol, quinidine, bepridil) with strong clinical TdP associations.[1]

Notably, high-quality platforms refine borderline compounds. Droperidol and domperidone, originally designated intermediate-risk, manifest high-risk-like FPD prolongation and arrhythmias in sensitive assays, consistent with clinical concerns and primary cardiomyocyte studies.[1] Enhanced chlorpromazine-risk detection, historically underestimated in some systems, underscores the advantage of platforms with mature ion channel expression and ventricular enrichment.[1] CiPA-ready platforms thus function not merely as confirmatory tools but as sensitive systems capable of refining and reclassifying clinical risk categories (Figure 2).[1]



*Figure 2. Classification of compound-induced QT prolongation risk in hiPSC-derived cardiomyocytes. (A) Summary of predefined thresholds used to categorise compounds as low, intermediate, or high risk based on percentage changes in field potential duration (FPD) relative to control. (B–D) Dose-dependent effects on FPD induced by representative low-, intermediate- and high-risk compounds, with values normalised to vehicle-treated controls. (E) Heatmap displaying all tested compounds ranked by normalised FPD, annotated with established risk categories and grouped according to increasing QT prolongation, with colour coding indicating low (green), intermediate (yellow) and high (red) risk. Data are presented as mean ± SD (n = 3–5 independent experiments); *p < 0.05, **p < 0.01 versus control.*

Regulatory Landscape and Future Directions

These advances align with an evolving regulatory environment explicitly supporting non-animal, human-relevant methodologies. The FDA Modernization Act 2.0 (2022) endorses advanced *in vitro* and *in silico* approaches in drug development and regulatory safety assessment, reinforcing the importance of human-relevant platforms like hiPSC-CMs for safer drug discovery with reduced animal reliance.[1,13]

The field advances toward three-dimensional, mechanically and electrically conditioned tissue constructs emulating native myocardial architecture.[1,11] Ventricular-enriched hiPSC-CMs optimised for 2D CiPA assays serve as building blocks for 3D engineered heart tissues and bioprinted patches, where mechanical loading and electrical pacing further enhance maturation and tissue-level biomechanics.[1,11] Integration with controlled mechanical stretch and pacing enhances sarcomeric organisation, calcium handling and force generation, progressively closing the translational gap between *in vitro* models and adult human cardiac physiology.[1]

CiPA-qualified hiPSC-CM platforms supported by rigorous phenotypic, transcriptomic and functional validation demonstrating HESI concordance are well positioned for future regulatory cardiac safety packages.[1,2,3] Their scalability, high-throughput compatibility, technical accessibility and potential extension into 3D cardiac organoids make them attractive for discovery triage through mechanistic risk assessment.[1,2,3,16] Their human derivation and mechanistic fidelity align with contemporary regulatory emphasis on translationally relevant, ethically sound and scientifically rigorous safety assessment.[1]

Conclusion (Stand out – Colour coded)

CiPA-qualified hiPSC-derived cardiomyocytes represent a convergent solution to long-standing challenges in cardiac safety testing and drug development. These human-relevant, mechanistically informative, technically scalable platforms align with emerging non-animal testing expectations. By combining high-purity ventricular-like phenotypes with comprehensive structural, molecular and functional characterisation, CiPA-ready hiPSC-CM systems provide a robust foundation for accurate, efficient and ethically sound assessment of proarrhythmic risk, cardiotoxic liability and overall cardiac safety across the drug development continuum. As regulatory frameworks evolve to support non-animal testing, these platforms are poised to play an increasingly central role in protecting patients while accelerating safer, more effective pharmaceutical development.

REFERENCES

1. Konala, V.B.R., Kuhikar, R., More, S., Gossmann, M., Lickiss, B., Linder, P., Sarkar, J., Bhanushali, P. & Khanna, A. CiPA-qualified human iPSC-derived cardiomyocytes: A new frontier in toxicity testing by evaluating drug-induced arrhythmias. Toxicol. *In Vitro* 108, 106100 (2025).
2. Sager, P.T., Gintant, G., Turner, J.R., Pettit, S. & Stockbridge, N. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the cardiac safety research consortium. Am. Heart J. 167, 292–300 (2014).
3. Colatsky, T., Fermini, B., Gintant, G., Pierson, J.B., Sager, P., Sekino, Y., Strauss, D.G. & Stockbridge, N. Comprehensive *in vitro* proarrhythmia assay (CiPA) – update on progress. J. Pharmacol. Toxicol. Methods 81, 15–20 (2016).
4. Fung, M., Thornton, A., Mybeck, K. et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets – 1960 to 1999. Ther. Innov. Regul. Sci. 35, 293–317 (2001).
5. Onakpoya, I.J., Heneghan, C.J. & Aronson, J.K. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Med. 14, 10 (2016).
6. Singh, B.N., Connolly, S.J., Crijns, H.J.G.M. et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357, 987–999 (2007).

7. Frothingham, R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 21, 1468–1472 (2001).
8. Funk, K.A. & Bostwick, J.R. A comparison of the risk of QT prolongation among SSRIs. Ann. Pharmacother. 47, 1330–1341 (2013).
9. Johannesen, L., Vicente, J., Mason, J.W., Sanabria, C., Waite-Labott, K., Hong, M., Guo, P., Lin, J., Sorensen, J.S., Galeotti, L. et al. Differentiating drug-induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin. Pharmacol. Ther. 96, 549–558 (2014).
10. Seyhan, A.A. Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. Transl. Med. Commun. 4, 18 (2019).
11. Ronaldson-Bouchard, K., Ma, S.P., Yeager, K., Chen, T., Song, L., Sirabella, D., Morikawa, K., Teles, D., Yazawa, M. & Vunjak-Novakovic, G. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature 556, 239–243 (2018).
12. Blinova, K., Dang, Q., Millard, D. et al. Comprehensive translational assessment of human-induced pluripotent stem cell-derived cardiomyocytes for evaluating drug-induced arrhythmias. Toxicol. Sci. 155, 234–247 (2017).
13. Text of the FDA Modernization Act 2.0. 117th Congress, S.5002 (2022). Available at: https://www.congress.gov/bill/117th-congress/senate-bill/5002/text, visited on 24 Jan 2026.
14. Gintant, G., Sager, P.T. & Stockbridge, N. Evolution of strategies to improve preclinical cardiac safety testing. Nat. Rev. Drug Discov. 15, 457–471 (2016).
15. Lundy, S.D., Zhu, W.Z., Regnier, M. & Laflamme, M.A. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 22, 1991–2002 (2013).
16. U.S. Food and Drug Administration. Roadmap to reducing animal testing in preclinical safety studies. FDA (2019). Available at: https://www.fda.gov/files/newsroom/published/roadmap_to_reducing_animal_testing_in_preclinical_safety_studies.pdf, visited on 24 Jan 2026.

Vijay Bhaskar Reddy Konala

Vijay Bhaskar Reddy Konala is a Principal Scientist at Yashraj Biotechnology and the first author with more than 15 years of experience in stem cell research. He is instrumental in study design and execution.

Email: vijay.konala@yashraj.com

Rutuja Kuhikar

Rutuja Kuhikar is a scientist and has optimised the hiPSC-cardiomyocyte differentiation protocol.

Email: rutuja.kuhikar@yashraj.com

Shruti More

Shruti More is a scientist and has been instrumental in performing the validation studies of hiPSC-cardiomyocytes.
shruti.more@yashraj.com

Matthias Gossmann

Matthias Gossmann is the CEO of Innovitro and has led the MEA studies of hiPSC-Cardiomyocytes.

Email: gossmann@innovitro.de

Bettina Lickiss

Bettina Lickiss is a scientist at Innovitro and has been involved in the MEA study conduction.

Email: lickiss@innovitro.de

Peter Linder

Peter Linder is the simulation scientist at Innovitro and has performed the simulation studies of this examination.

Email: linder@innovitro.de

Jaganmay Sarkar

Jaganmay Sarkar is a scientist and has done various batch generations of hiPSC- Cardiomyocytes.

Email: jaganmay.sarkar@yashraj.com

Paresh Bhanushali

Paresh Bhanushali is responsible for the overall study operations and fund approvals.

Email: paresh.bhnushali@yashraj.com

Amit Khanna

Amit Khanna is the corresponding author and lead scientist responsible for the overall study design, execution and cross-functional collaborations.

Email: amit.khanna@yashraj.com